3170 results for «231»
3170 results
Getting ready for tricuspid TEER: key steps in building a successful programme
14 Feb 2026 – From PCR Tokyo Valves 2026
Prepare to establish a successful tricuspid TEER programme by understanding essential components such as systematic echocardiographic and clinical assessments for patient selection, procedural fundamentals, and programme development supported by clinical evidence.
Coronary access and revascularisation in patients undergoing TAVI: from work-up to lifetime management
15 Feb 2026 – From PCR Tokyo Valves 2026
This session delves into the comprehensive management of ischemic heart disease in patients undergoing transcatheter aortic valve implantation (TAVI). It highlights the critical importance of maintaining coronary access post-TAVI and explores how various valve designs affect coronary accessibility, particularly in cases involving valve-in-valve (TAV-in-TAV) procedures, guiding...
Learn from the experts: lifetime management for Evolut first redo TAVI (TAV-in-TAV) and explant
14 Feb 2026 – From PCR Tokyo Valves 2026
This session offers an in-depth exploration of lifetime management strategies for patients undergoing Evolut first redo TAVI procedures, including TAV-in-TAV and explant techniques. It provides a comprehensive understanding of clinical decision-making algorithms, technical challenges, and key considerations for successful procedural planning and execution, supported by real-world...
Real world outcomes and strategies for optimal TEER across diverse DMR anatomies
14 Feb 2026 – From PCR Tokyo Valves 2026
This session develops a nuanced understanding of the complexity inherent in DMR cases, informed by the latest registry data. It highlights the capabilities of the PASCAL device in managing challenging anatomies and achieving predictable clinical results, alongside contemporary strategies for device selection and optimal placement to...
TAVI today and tomorrow: international trends and future direction
14 Feb 2026 – From PCR Tokyo Valves 2026
This session focuses on the evolving landscape of TAVI, emphasising lifetime management strategies with a focus on the first valve implanted. It provides a comprehensive discussion on representative patient profiles, current guidelines from various countries, and future outlooks, alongside recent long-term clinical results for the balloon-expandable...
New horizons in structural heart disease therapy - Cutting-edge stroke prevention devices: WATCHMAN × SENTINEL
15 Feb 2026 – From PCR Tokyo Valves 2026
This session delves into the advances in stroke prevention for patients undergoing TAVI with atrial fibrillation, focusing on left atrial appendage closure (LAAC) and cerebral protection strategies. It highlights the evolving role of WATCHMAN devices and the SENTINEL Cerebral Protection System, emphasising perioperative stroke risk management...
Protect the brain for TAVI - True potential of SENTINEL Cerebral Protection System
14 Feb 2026 – From PCR Tokyo Valves 2026
This session highlights the critical role of cerebral protection during TAVI procedures by focusing on the SENTINEL Cerebral Protection System. It reviews trends in the United States and Japan, presents clinical outcomes one year post-introduction in Japan, and examines key clinical trials through a meta-analysis comparing...
PCR Tokyo Valves 2026: Your travel guide featuring upcoming exclusive booking services and special deals.
Percutaneous or surgical management of post-infarction ventricular septal defects: The United Kingdom National Registry
17 Sep 2022
Elad Asher provides his take on the UK National Registry which was presented at the TCT congress 2022 by Joel Peter Giblett on behalf of the UK PIVSD investigators.
Author
OPTIMUM: Outcomes of Percutaneous RevascularizaTIon for Management of SUrgically Ineligible Patients with Multivessel or Left Main Coronary Artery Disease
04 Nov 2021
Mirvat Alasnag reviews the OPTIMUM trial, presented by David E. Kandzari, which reports outcomes in a subset of patients who are increasingly seen in modern day catheterization laboratories. It is noteworthy that 1 in 5 patients with left main or multivessel disease are considered surgically ineligible.
Author
